Clinical trials: Heparin-Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia Registry
The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortality rate.
- Trial name
- HIT (NCT00456326)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Brigham and Women's Hospital
Thrombosis, Heparin-induced Thrombocytopenia
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
This study will evaluate the use of a blood thinner, fondaparinux, which is approved for use in adults (not in children) in a children aged 1-18 years.
- Trial name
- NCT00412464
- Testing
- Fondaparinux
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital Los Angeles
Thrombocytopenia
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
Heparin-induced thrombocytopenia (HIT), a condition characterized by low platelet levels and possible blood clots, occurs in a small number of people after treatment with the drug heparin.
- Trial name
- HOT (NCT00594685)
- Where
- 21 sites in United States
- Volunteers
- 10 people
- Sponsor
- Carelon Research
Thrombocytopenia, Thrombosis
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT)…
- Trial name
- NCT00039858
- Testing
- Argatroban
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- Encysive Pharmaceuticals
Heparin Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals.
- Trial name
- HIT-RADIO (NCT01178333)
- Where
- 21 sites in United States
- Volunteers
- 668 people
- Sponsor
- Carelon Research
Heparin Induced Thrombocytopenia (HIT)
Heparin Induced Thrombocytopenia: Pharmacoeconomics
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study.
- Trial name
- NCT00456001
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Brigham and Women's Hospital
Heparin-induced Thrombocytopenia
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)
- Trial name
- HITSOVA (NCT03809481)
- Testing
- Danaparoid Sodium, Argatroban
- Where
- 35 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 7 people
- Sponsor
- Aspen Global Incorporated